Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
ProMIS Neurosciences, Inc. (NASDAQ:PMN) is a Canadian biotechnology company founded in 2004 and headquartered in Toronto. Originally incorporated as Amorfix Life Sciences Ltd., the company rebranded to ProMIS Neurosciences in July 2015 to better reflect its focus on precision medicine for neurodegenerative diseases. The company went public in 2007 and currently trades on NASDAQ. ProMIS specializes in developing targeted therapies for devastating neurological conditions including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy, using proprietary computational algorithms to identify novel drug targets.
Latest newsMore news →
Promis Neurosciences reported its second-quarter 2026 financial results.37d agoProMIS Neurosciences reported positive blinded six-month interim safety and biomarker data for its drug candidate PMN310 in the PRECISE-AD Phase 1b Alzheimer's disease trial.54d agoProMIS Neurosciences reported first human evidence of amyloid-beta oligomer target engagement by PMN310 at AAIC 2026.68d ago